# A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome

> **NCT01894958** · PHASE2 · COMPLETED · sponsor: **Neuren Pharmaceuticals Limited** · enrollment: 72 (actual)

## Conditions studied

- Fragile X Syndrome

## Interventions

- **DRUG:** NNZ-2566
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01894958
- **Lead sponsor:** Neuren Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-09
- **Final completion:** 2015-10
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01894958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01894958, "A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01894958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*